Abbreviation Term
ALL Acute lymphoblastic leukemia
AML Acute myelogenous leukemia
AR Allelic ratio
AT/RT Atypical teratoid/rhabdoid tumor
AYA Adolescent and young adult
BDG Beta-D-glucan
BMT CTN Blood and Marrow Clinical Trials Network
Bu-Cy-Mel Busulfan-cyclophosphamide-melphalan
Bu-Flu Busulfan-fludarabine
CAR-T Chimeric antigen receptor T cell
CCL Cancer Control
CEM Carboplatin-etoposide-melphalan
cGVHD Chronic GVHD
CMV Cytomegalovirus
CNS Central nervous system
COG Children’s Oncology Group
CT Cellular Therapy and Stem Cell Transplantation Committee
CTEP Cancer Therapy Evaluation Program
DFS Disease free survival
EBV Epstein Barr virus
EFS Event free survival
FACT Foundation for the Accreditation of Cellular Therapy
FDA U.S. Food and Drug Administration
FLT3 Fms-like tyrosine kinase
GI Gastrointestinal
GVHD Graft-versus-Host disease
GVL Graft-versus-leukemia
HCT Hematopoietic cell transplantion
HLA Human leukocyte antigen
HR Hazard ratio
IFD Invasive fungal disease
IgH Immunoglobulin heavy chain
JMML Juvenile myelomonocytic leukemia
KIR Killer immunoglobulin receptor
LD IL-2 Low dose interleukin-2
MAGIC Mount Sinai Acute Graft versus Host Disease International Consortium
MDS Myelodysplastic syndrome
MRD Minimal residual disease
MUD Matched unrelated donor
NB Neuroblastoma
NGS Next-generation sequencing
OS Overall survival
PTCTC Pediatric Transplant and Cellular Therapy Consortium
PTCy/Tac/MMF Post-HCT cyclophosphamide with tacrolimus and mycophenolate
PTLD Post-transplant lymphoproliferative disorder
SOT Solid organ transplant
TBI Total body irradiation
TCR T-cell receptor
TKI Tyrosine kinase inhibitor
TRM Transplant related mortality
UCB Umbilical cord blood
V[D]J Variable, diversity, and joining
VOD/SOS Veno-occlusive disease/sinusoidal obstructive syndrome
VSTs Virus-specific T-cells
131I-MIBG 131I-meta-iodobenzylguanidine